Debt and equity financing · Biotech
4Moving Biotech closes €12m debt and equity financing
Private investors and family offices back the next clinical proof-of-concept milestone for its knee-osteoarthritis program.
A mixed financing after public grant support
The financing combines equity and loans invested directly in the 4P-Pharma subsidiary. The announcement does not disclose individual investors or describe the transaction as a Series A.
It follows a €7.6 million France 2030 i-Démo grant and the extension of the INFLAM MOTION trial to the United States. The company said the new capital extended its runway to Phase 2a data; its approximately €30 million total funding includes both private capital and public support.
Funding history
Debt and equity financing · This round€12M